Research
Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce
Business, Research“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.
Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin
Business, Research
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it.
The Phase-2…
Parents Are Very Open to Ketamine Therapy for Kids, Study Finds
Research“As parents maintain decision-making capacity of their child’s medical care, parental consent is a key factor in the adoption of new treatments for adolescents," study authors explain.
Psychedelic Users Experienced Less Psychological Stress During COVID-19 Lockdowns, Study Finds
ResearchResearchers found stress further reduced for the participants that use psychedelic drugs at least once every six months.
FDA Authorizes Cybin Device to Quantify Psychedelics’ Effects on the Brain
Research"This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," says Cybin's chief clinical officer.
Psychedelics Help Heal Childhood Trauma, Study Finds
ResearchResearchers find that there were significantly lower levels of complex trauma symptoms and feelings of internalized shame in study participants that had used psychedelics therapeutically.
Psilocybin Study for Tobacco Addiction Receives First Federal Psychedelics Research Grant in 50 Years
ResearchA Johns Hopkins Medicine professor says "it was only a matter of time," while lead researcher calls the historic grant "monumental" for the psychedelics movement.
This New Company Believes Psychedelics Can Treat Dementia
ResearchThere is currently no known cure for dementia, but Return Health CEO Dr. James Kuo says psychedelics offer "unprecedented" potential.